Aquestive Therapeutics, Inc. (AQST)
AQST Stock Price Chart
Explore Aquestive Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AQST price movements and trends.
AQST Company Profile
Discover essential business fundamentals and corporate details for Aquestive Therapeutics, Inc. (AQST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jul 2018
Employees
142.00
Website
https://www.aquestive.comCEO
Daniel Barber
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Financial Timeline
Browse a chronological timeline of Aquestive Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$0.13, while revenue estimate is $12.94M.
Earnings released on 11 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%, while revenue for the quarter reached $10.00M , missing expectations by -17.98%.
Earnings released on 12 May 2025
EPS came in at -$0.24 falling short of the estimated -$0.17 by -41.18%, while revenue for the quarter reached $8.72M , missing expectations by -28.70%.
Earnings released on 5 Mar 2025
EPS came in at -$0.19 falling short of the estimated -$0.14 by -35.71%, while revenue for the quarter reached $11.87M , missing expectations by -9.50%.
Earnings released on 4 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.12 by -8.33%, while revenue for the quarter reached $13.54M , beating expectations by +3.17%.
Earnings released on 6 Aug 2024
EPS came in at -$0.03 surpassing the estimated -$0.11 by +72.73%, while revenue for the quarter reached $20.10M , beating expectations by +62.35%.
Earnings released on 7 May 2024
EPS came in at -$0.17 falling short of the estimated -$0.09 by -88.89%, while revenue for the quarter reached $12.05M , missing expectations by -1.69%.
Earnings released on 5 Mar 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $13.21M , beating expectations by +13.55%.
Earnings released on 6 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.11 by +72.73%, while revenue for the quarter reached $13.00M , beating expectations by +11.80%.
Earnings released on 7 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $13.24M , beating expectations by +20.26%.
Earnings released on 2 May 2023
EPS came in at $0.11 surpassing the estimated -$0.10 by +210.00%, while revenue for the quarter reached $11.13M , beating expectations by +12.24%.
Earnings released on 7 Mar 2023
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $10.68M , beating expectations by +2.51%.
Earnings released on 1 Nov 2022
EPS came in at -$0.23 surpassing the estimated -$0.30 by +23.33%, while revenue for the quarter reached $11.46M , beating expectations by +4.19%.
Earnings released on 2 Aug 2022
EPS came in at -$0.36 surpassing the estimated -$0.41 by +12.20%, while revenue for the quarter reached $13.27M , beating expectations by +25.47%.
Earnings released on 3 May 2022
EPS came in at -$0.32 surpassing the estimated -$0.45 by +28.89%, while revenue for the quarter reached $12.27M , beating expectations by +21.13%.
Earnings released on 8 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.37 by -2.70%, while revenue for the quarter reached $11.08M , beating expectations by +18.33%.
Earnings released on 2 Nov 2021
EPS came in at -$0.37 surpassing the estimated -$0.40 by +7.50%, while revenue for the quarter reached $13.29M , beating expectations by +20.68%.
Earnings released on 3 Aug 2021
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $15.35M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $11.12M , beating expectations by +78.24%.
Earnings released on 9 Mar 2021
EPS came in at -$0.60 falling short of the estimated -$0.46 by -30.43%, while revenue for the quarter reached $7.15M .
Earnings released on 4 Nov 2020
EPS came in at -$0.49 surpassing the estimated -$0.50 by +2.00%, while revenue for the quarter reached $8.26M , beating expectations by +6.52%.
AQST Stock Performance
Access detailed AQST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.